Skip to main content

HOPA Abstracts

Veterans Health Administration Pharmacy Benefits Management Anti-Cancer Stewardship Pilot: Why Switch to a Second-Line Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia?

Abstract #CR22

Assessment and Education of Biosimilars Across an Outpatient Oncology Infusion Network

Abstract #CR23

Optimizing Corticosteroid Use for Immune-Related Adverse Events at a Community Oncology Practice

Abstract #LB01

Efficacy of Tixagevimab-Cilgavimab in Preventing SARS-CoV-2 in Patients with Hematologic Malignancies

Abstract #LB02

Potentially Inappropriate Medication Use and Cognition in Older Women with Breast Cancer

Abstract #LB03

Safety and Tolerability of an Alternative Capecitabine Dosing Schedule in Patients with Colorectal Cancer

Abstract #LB04

Biosimilar Uptake and Cost-Savings Analysis Before and After the Implementation of a Pharmacist-Driven Substitution Program Within a National Community Oncology Network

Abstract #CR02

Bruton Tyrosine Kinase Inhibitors: Real-World Clinical Outcomes in a Diverse Patient Population at a Large Safety Net Hospital

Abstract #CR03

Clinical Outcomes in Patients with Tumor PD-L1 Less Than 1% Who Received First-Line Nivolumab plus Ipilimumab and 2 Cycles of Chemotherapy versus Chemotherapy Alone for Metastatic NSCLC: Results from CheckMate 9LA

Abstract #CR04

HOP(A) Springs Eternal

By Bryna Delman Ewachiw, PharmD, BCOP; Mark L. Zangardi, PharmD, BCOP

5
6
7
8
9
10
11

Page 8 of 12
Results 71 - 80 of 119